Sienna Gestion Takes $917,000 Position in Abbott Laboratories $ABT

Sienna Gestion acquired a new stake in Abbott Laboratories (NYSE:ABT) in the fourth quarter, HoldingsChannel reports. The fund acquired 7,327 shares of the healthcare product maker’s stock, valued at approximately $917,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Tobias Financial Advisors Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $298,000. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in shares of Abbott Laboratories by 1.7% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 7,855 shares of the healthcare product maker’s stock worth $984,000 after buying an additional 135 shares during the period. USS Investment Management Ltd boosted its holdings in shares of Abbott Laboratories by 0.7% during the 4th quarter. USS Investment Management Ltd now owns 290,576 shares of the healthcare product maker’s stock worth $36,402,000 after buying an additional 2,151 shares during the period. WealthTrust Axiom LLC boosted its holdings in shares of Abbott Laboratories by 3.2% during the 4th quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker’s stock worth $384,000 after buying an additional 94 shares during the period. Finally, Zinnia Wealth Advisory LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter worth about $407,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $88.76 on Tuesday. The company has a 50 day moving average of $91.17 and a 200-day moving average of $107.56. The company has a market cap of $154.60 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the business posted $1.09 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of several research analyst reports. Stifel Nicolaus reduced their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Citigroup reduced their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. UBS Group dropped their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Finally, Royal Bank Of Canada dropped their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.38.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.